LNTH Company Profile and Key Details

Q: Who are the executives of LNTH?

Mr. Mark Richard KinarneySenior Director of Investor RelationsMr. Etienne MontagutChief Bus. OfficerMs. Linda S. LennoxVice President of Corporation Communications & Chief of StaffMelissa DownsDirector of Corporation CommunicationsMs. Mary Anne HeinoChief Executive Officer & DirectorMr. Paul M. BlanchfieldPresMr. Robert J. Marshall Jr., CFAChief Financial OfficerMs. Ying YaoChief HR OfficerMr. Daniel M. NiedzwieckiChief Admin. Officer, Gen. Counsel & Corporation Sec.Ms. Andrea SabensChief Accounting OfficerMs. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMs. Carol WalkerSenior Vice President of Quality

NASDAQ : LNTH

Lantheus

$67.98

2.055+3.12%

Open: 12:47 PM

74.13

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lantheus Holdings, Inc. (LNTH) stock surged +3.12%, trading at $67.98 on NASDAQ, up from the previous close of $65.92. The stock opened at $65.31, fluctuating between $65.26 and $68.13 in the recent session.

Stock Snapshot

65.92

Prev. Close

4.65B

Market Cap

65.26

Day Low

28.21

P/E Ratio

2.41

EPS (TTM)

3.78

Cash Flow per Share

65.31

Open

68.4M

Number of Shares

68.13

Day High

92.92%

Free Float in %

11.91

Book Value

334.77K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	64.50	66.41	64.35	65.92	2.55M
Dec 17, 2025	65.21	67.01	64.83	65.24	1.26M
Dec 16, 2025	65.48	66.86	64.96	65.17	1.25M
Dec 15, 2025	66.36	67.40	66.08	66.57	1.29M
Dec 12, 2025	64.42	67.35	64.42	66.62	1.55M
Dec 11, 2025	61.21	63.50	61.21	63.10	1.14M
Dec 10, 2025	61.41	61.68	60.15	60.82	783.02K
Dec 09, 2025	62.16	63.03	60.57	60.88	1.03M
Dec 08, 2025	62.96	63.38	62.19	62.27	1.15M
Dec 05, 2025	62.04	64.23	61.25	63.30	1.21M
Dec 04, 2025	59.83	62.60	59.14	61.87	1.32M
Dec 03, 2025	58.75	60.36	58.75	59.77	855.03K
Dec 02, 2025	59.01	60.14	57.94	58.55	946.21K
Dec 01, 2025	58.41	59.13	57.44	59.08	1.09M
Nov 28, 2025	58.71	58.87	58.24	58.87	362.22K
Nov 26, 2025	58.83	59.30	57.91	58.75	767.14K
Nov 25, 2025	56.85	59.25	56.74	59.06	964.37K
Nov 24, 2025	55.74	57.15	54.94	56.49	1.15M
Nov 21, 2025	53.44	57.35	53.38	55.82	1.31M
Nov 20, 2025	52.85	54.70	52.80	53.59	1.01M

Contact Details

Bedford, MA 01862

United States

https://www.lantheus.com 978 671 8001

About Company

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Stock Peers

NBIX

3.16+2.23%

Neurocrine Biosciences, Inc.$145.00 ITCI

Intra-Cellular Therapies, Inc.$131.87 ANIP

0.02+0.02%

ANI Pharmaceuticals, Inc.$82.85 SUPN

2.2+4.46%

Supernus Pharmaceuticals, Inc.$51.48 COLL

-0.45-0.91%

Collegium Pharmaceutical, Inc.$48.88 HROW

1.84+4.13%

Harrow Health, Inc.$46.40 PAHC

-3.16-7.82%

Phibro Animal Health Corporation$37.25 INDV

-0.33-0.93%

Indivior PLC$35.21 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 AMPH

0.1+0.38%

Amphastar Pharmaceuticals, Inc.$26.60

Company Overview

Lantheus Holdings, Inc. (NASDAQ:LNTH) closed at $67.97 USD, gaining $2.05 (3.12%) from the previous close of $65.92. The stock is currently mid-range between its 52-week high and low $47.25 and $111.29. With a market capitalization of about $4.65 billion, Lantheus Holdings, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.10). Key stats such as the average daily volume over the past year has been around 1.39 million shares, volume is running light vs its 52-week average. Headquartered in Bedford, MA, Lantheus Holdings, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Brian A. Markison, the company employs approximately 808 people and listed since June 25, 2015. Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Technical Performance

LNTH has shown sold momentum, gaining 4.47% over the past week and 30.77% over the past quarter, though year-to-date performance is down -26.31%. Short-term trend indicators are mixed aligned (SMA20 6.93%, SMA50 14.18%, SMA200 -8.54%). The stock’s 14-day RSI is 67.49 (firm momentum), while the ATR of 2.24 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -40.77% below its high and over 39.51% above its low. Average 10-day trading volume of 1.58 million shares is slightly above the 3-month average of 1.32 million, indicating heightened recent market interest.

Valuation Metrics

Lantheus Holdings, Inc. trades at a P/E ratio of 26.43, slightly below the S&P 500 average, with a price-to-sales ratio of 2.95 and a price-to-book ratio of 3.96 trading at moderately above to book value. The P/FCF stands at 10.89, also above market averages.

Dividend & Fair Value

Lantheus Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $304.28. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Lantheus Holdings, Inc. generated EPS of $2.38 over the past year. Five-year average earnings growth is 40.75%. Wall Street analysts project EPS growth of -0.65% annually over the next five years. The latest quarter delivered EPS of $0.41. The next quarter is forecast at $1.19. Next year's EPS is expected at $4.94. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 7 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $127.00 to $61.00. The high target offers 92.66% upside. The low target suggests -7.46% downside. The mean target is $86.57. This offers 31.33% upside. Lantheus Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -67.69%. The prior quarter beat by -4.27%. Over the last six quarters, Apple has recorded several small beats. These include -51.97% in July 31, 2024.

Shareholding & Insider Activity

Lantheus Holdings, Inc. has 67.99 million shares outstanding. The public float is 59.94 million shares, elevated short interest at 16.39% of float. This equals 8.42 million shares. The short ratio is 8.25 days. Institutional investors hold 119.95% of the float. Insiders own 2.24%. PATEL RAJIV A holds 3.48 million shares, FARALLON PARTNERS L L C/CA has 3.48 million shares and Heino Mary Anne has 318.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.82 million shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lantheus generated $1.30B in revenue, or $18.46 per share. Gross margin was 54.73%, operating margin 28.13%, and net profit margin 25.20%. Returns are exceptional, with ROA at 19.78% and ROE at 40.04%.
On valuation metrics, Lantheus trades at a P/E of 26.43, P/S of 2.95 and P/B of 3.96. The current ratio is 2.67 and quick ratio is 2.49. Operationally, the company’s inventory turnover is 9.29 and cash conversion cycle is 81.35 days. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of 525.48.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Lantheus posted revenue of $1.30B, down slightly from $935.06M in the prior quarter. Gross profit was $709.54M (margin 54.73%). Operating income was $364.64M (margin 28.1%). Net income was$326.66M (EPS $4.79).
The company ended the quarter with $713.66M in cash and short-term investments, a total debt of $616.95M, and net debt of - $96.71M. Total assets were $1.65B, with equity of $815.89M. Financials further reflected stability, with operating cash flow of $305.26M, free cash flow of $258.71M, and capital expenditures of - $46.56M.

Price Forecast & Outlook

Our AI price prediction model suggests that Lantheus Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.8%, with price expected at $71.72 by January 02, 2026, within a range of $69.78 to $73.64 3-Month Outlook: Projected rise of 25.65%, reaching $82.83 by March 19, 2026, with a range of $75.74 to $88.15. 1-Year Outlook: Projected loss of -1.46%, with price at $64.96 by December 18, 2026, within a range of $59.59 to $72.80.

Key Takeaways

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares are down -26.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lantheus Holdings, Inc. trading at a premium to the broader market with a P/E of 26.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $99.93, suggesting 51.59% upside. Our AI forecast model points to short-term strength (8.8% over two weeks), a medium-term rise (25.65% over three months), and a longer-term loss (-1.46% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Lantheus Holdings, Inc. (LNTH) stock price?

Lantheus Holdings, Inc. (NASDAQ: LNTH) stock price is $67.98 in the last trading session. During the trading session, LNTH stock reached the peak price of $68.13 while $65.26 was the lowest point it dropped to. The percentage change in LNTH stock occurred in the recent session was 3.12% while the dollar amount for the price change in LNTH stock was $2.06.

LNTH's industry and sector of operation?

The NASDAQ listed LNTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Lantheus Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LNTH?

Mr. Mark Richard Kinarney
Senior Director of Investor Relations
Mr. Etienne Montagut
Chief Bus. Officer
Ms. Linda S. Lennox
Vice President of Corporation Communications & Chief of Staff
Melissa Downs
Director of Corporation Communications
Ms. Mary Anne Heino
Chief Executive Officer & Director
Mr. Paul M. Blanchfield
Pres
Mr. Robert J. Marshall Jr., CFA
Chief Financial Officer
Ms. Ying Yao
Chief HR Officer
Mr. Daniel M. Niedzwiecki
Chief Admin. Officer, Gen. Counsel & Corporation Sec.
Ms. Andrea Sabens
Chief Accounting Officer
Ms. Dorothy Barr
Senior Vice President of Manufacturing & Technical Operations
Ms. Carol Walker
Senior Vice President of Quality

How LNTH did perform over past 52-week?

LNTH's closing price is 39.51% higher than its 52-week low of $47.25 where as its distance from 52-week high of $111.29 is -40.77%.

How many employees does LNTH have?

Number of LNTH employees currently stands at 808.

Link for LNTH official website?

Official Website of LNTH is: https://www.lantheus.com

How do I contact LNTH?

LNTH could be contacted at phone 978 671 8001 and can also be accessed through its website. LNTH operates from 331 Treble Cove Road, Bedford, MA 01862, United States.

How many shares of LNTH are traded daily?

LNTH stock volume for the day was 334.77K shares. The average number of LNTH shares traded daily for last 3 months was 1.39M.

What is the market cap of LNTH currently?

The market value of LNTH currently stands at $4.65B with its latest stock price at $67.98 and 68.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	808
Beta	-0.1
Sales or Revenue	$1.30B
5Y Sales Change%	1.115%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

LNTH Company Profile and Key Details

Lantheus

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Price Forecast & Outlook

Earnings & Analyst Outlook

Key Takeaways

Valuation Metrics